Our breakthrough technology combines synthetic and stem cell biology, offering limitless possibilities. Enabling a new generation of cell therapies, providing the best human cells for research and drug discovery, and allowing the control of advanced synthetic biology circuits for biomanufacturing.
Application: precise reprogramming of stem cells
Reprogramming stem cells into functional skeletal muscle
(9-day time course; final contraction assay by addition of acetylcholine)
Batch to batch reproducibility for applications including high throughput screening and cell therapy
Unprecedented purity results compared to current technologies.
Industrial-scale quantities and order-of-magnitude lower costs
Production takes days not months results in significant associated benefits
Biology turns engineering
As we reach the “read/write” stage of biology, evolution is proving to be the ultimate algorithm, allowing us to increasingly program biological systems. A foundational shift in biology from being an empirical science towards becoming an engineered discipline is underway.
MD, SAB Member
Ramy is a leading immuno-oncology clinician who has helped to develop some of the breakthrough therapies in this field. Ramy has served as the Vice President of Clinical Development for Immuno-oncology at AstraZeneca, and as a member of the Bristol-Myers Squibb Immuno-oncology program. Ramy is currently the Chief Medical Officer at the Parker Institute of Cancer Immunotherapy.
MD, PhD, Founder/CEO
Mark is a stem cell biologist and neurosurgeon at the University of Cambridge. By combining synthetic and stem cell biology, his team has developed a benchmark technology for the efficient and consistent production of human cells for use in research, drug development, and cell therapy. He is the founder of Bit Bio and co-founder of the cultured meat startup Meatable.
PhD, Chief Business Officer
Paul is a serial entrepreneur and scientist with over thirty years of experience in the biotech and pharma sectors. Most recently, he was the commercial founder and President of Horizon Discovery Group, and founder of CellRx Limited, a growth factors company serving the biopharmaceutical sector. Paul holds a PhD in Biotechnology from the University of Cambridge.
PhD, Chief Scientific Advisor
Roger is a pioneer and thought leader in the field of human stem cell biology. His lab was the first to isolate pluripotent epiblast stem cells from the epiblast layer of the developing mammalian embryo. In addition, he developed one of the first cellular reprogramming protocols. Roger was co-founder of the Cambridge Stem Cell Institute. His lab is currently focused on differentiation of pluripotent stem cells, with potential applications for drug discovery, toxicity testing and cell therapies.
CFO / COO
Florian is an active entrepreneur and investor. He is the co-founder of Bit Bio. Previously, he was CFO & Head of Strategic Partnerships for Tessa Therapeutics, a clinical-stage cell therapy company. Florian is a former investment banker, a graduate of the Stanford School of Engineering, and an alumnus of Harvard Business School.
PhD, SAB Member
Marius’ seminal 2010 paper in Nature demonstrating direct conversion of fibroblasts into neurons has sparked a widespread interest in cell reprogramming. He is the co-director of the Stanford Stem Cell Institute. His lab uses cellular reprogramming to understand how neurons are induced, and how they mature and maintain their identity.
Published on TechCrunch.
Bit Bio, the new startup that pitches itself as the “enter button for the keyboard to the software of life,” only needed three weeks to raise its latest $41.5 million round of funding.
Sure, Bit Bio got some significant cash for its cell coding work. But it’s the insiders who are backing them that will garner the attention
Published on Endpoints News.
Mark Kotter’s synthetic biology team at Bit Bio has already won lots of local recognition in the UK for its tech for precision reprogramming of stem cells at an industrial scale. Now they have a jolt of cash from some marquee US investors to fuel the work and drive some added global panache for the biotech’s profile.
Published on Cambridge Independent.
Discovery Drive-based synthetic biology specialist Bit Bio has closed a $41.5million Series A investment, bringing the company’s total funding to $50million.
Rick Klausner, Bob Nelsen, and Jim Tananbaum team up with Bit Bio to uncover the “operating system of life” and accelerate the company’s drive...
Webinar - on demand Speakers: Prof Hagan Bayley & Dr Mark Kotter Monday June 29 4pm GMT | 8am PST | 11am EST 60 minutes Listen to our...
Join us at ISSCR 2020 where we will be exhibiting!
Bit Bio Secures Distribution Agreement with Abcam to Democratize Access to Human Cells for Global Life Science Research
Published on PR Newswire.
Bit Bio announces agreement with Abcam, a global innovator in life science reagents and tools, to make Bit Bio’s iPSC derived functional human cells widely available to the global life science community.
Charles River Announces Strategic Partnership with Bit Bio, Increasing Portfolio of Translational Drug Discovery Technologies
Published on Business Wire.
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an exclusive Discovery and Safety Services partnership with Bit Bio, a company that offers consistent and efficient reprogramming of human cells for use in research, drug discovery, and cell therapies.
Published on BioSpace.
Bit Bio, a Cambridge University startup, added a number of industry luminaries to its leadership team to support its moonshot goal of developing a scalable platform technology capable of producing any human cell type.
Published on Medium.
Learn about the potential of cellular reprogramming from bit bio founder Mark Kotter.